LATS1 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA517142-Each-of-1 | In Stock | ₹ 40,406.00 |
PIPA517142 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 40,406.00
GST (18%): ₹ 7,273.08
Total Price: ₹ 47,679.08
Antigen
LATS1
Classification
Polyclonal
Formulation
0.01M HEPES with 0.15M NaCl, 100μg/mL BSA, 50% glycerol and no preservative; pH 7.5
Gene Accession No.
O95835
Gene Symbols
LATS1
Immunogen
Synthetic peptide corresponding to amino acids surrounding Ser177 of human LATS1
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Non-human Primate
Product Type
Antibody
Isotype
IgG
Applications
Western Blot
Conjugate
Unconjugated
Gene
LATS1
Gene Alias
AW208599; h-warts; large tumor suppressor; large tumor suppressor homolog 1; large tumor suppressor kinase 1; large tumor supressor, homolog 1; LATS (large tumor suppressor, Drosophila) homolog 1; LATS, large tumor suppressor, homolog 1; lats1; RGD1564085; Serine/threonine-protein kinase LATS1; WARTS; WARTS protein kinase; wts
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
9113
Content And Storage
-20°C
Form
Liquid
Related Products
Description
- It is not recommended to aliquot this antibody
- LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis which is phosphorylated in a cell-cycle dependent manner
- The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity which indicating a role as a negative regulator of CDC2/cyclin A and the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding
- LATS1 act as a tumor suppressor and play an important role in the development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.